{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Katie Banister, Jonathan A Cook, Graham Scotland, Augusto Azuara-Blanco, Beatriz Goulão, Heinrich Heimann, Rodolfo Hernández, Ruth Hogg, Charlotte Kennedy, Sobha Sivaprasad, Craig Ramsay & Usha Chakravarthy.

Katie Banister ¹, Jonathan A Cook ², Graham Scotland ^1,3, Augusto Azuara-Blanco ⁴, Beatriz Goulão ¹, Heinrich Heimann ⁵, Rodolfo Hernández ³, Ruth Hogg ⁴, Charlotte Kennedy ³, Sobha Sivaprasad ⁶, Craig Ramsay ¹, Usha Chakravarthy ^4,*

¹ Health Services Research Unit, University of Aberdeen, Aberdeen, UK
² Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
³ Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
⁴ Centre for Public Health, Queen’s University Belfast, Belfast, UK
⁵ Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
⁶ National Institute for Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK
^* Corresponding author Email: u.chakravarthy@qub.ac.uk

Declared competing interests of authors: Usha Chakravarthy received funding from Novartis (Basel, Switzerland) relating to the FASBAT study, which is an externally led (University of York, York) add-on to the EDNA study. Augusto Azuara-Blanco contributed to the Health Technology Assessment (HTA) Prioritisation Committees A (out of hospital; 2019–20) and B (in hospital; 2020 to present). Jonathan A Cook was a member of the HTA Efficient Study Designs and End-of-Life Care and Add-on Studies Boards (2014–16). Ruth Hogg contributes to an Advisory Board for Roche (Basel, Switzerland). Sobha Sivaprasad reports Honoraria for Advisory Board Attendance for Novartis, Bayer (Leverkusen, Germany), Allergan Inc. (Dublin, Ireland). Sobha Sivaprasad also reports grants from an investigator-initiated study from Allergan Inc.; a clinical research fellow salary from Bayer; Principal Investigator commercially sponsored studies from Novartis, Bayer and Allergan; advisory board attendance from Boehringer and Roche; a research grant from Boehringer; speaker fees and non-financial support from a research grant from Optos (Dunfermline, UK); and membership of the HTA Commissioning Committee (2017–present). Craig Ramsay is a Member of the National Institute for Health Research (NIHR) HTA General Board (2017–present). Usha Chakravarthy reports travel expenses for NIHR topic selection panel membership; advisory board fees (Alimera Sciences; Roche), Chair of International DMC for Trials (Bayer), consultation fees for research studies (Apellis); speaker fees (Novartis), membership of HTA IP Panel (2013–18) and HTA Prioritisation Committee B (2013–19).